文献速递MDS 与骨髓增殖性肿瘤白血病

芦可替尼治疗老年骨髓纤维化患者:年龄与基因型的影响——一项针对291例老年患者的多中心研究

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
PubMed 文献 · Br J Haematol · 2018-07-16

该多中心回顾性研究在23个欧洲血液学中心分析291例≥65岁接受芦可替尼治疗的骨髓纤维化患者,评估年龄与分子基因型对疗效、毒性和生存的影响;≥75岁患者疗效与65-74岁患者相当,但药物诱导贫血和血小板减少发生率更高、生存更差;高危分子突变显著影响生存并对冲年龄效应。

要点

  • ≥75岁与65-74岁患者对芦可替尼的疗效相当,但≥75岁患者药物诱导贫血和血小板减少发生率更高、生存更差。
  • 两年龄组芦可替尼停药率相当,分子异常数目和类型在年龄组间也相当。
  • 高危分子突变显著影响生存并对冲年龄效应,≥75岁患者若高危突变基因<2个,生存与≥2个高危突变的65-74岁患者相当。

核心结论

  • 由于疗效不受年龄影响,高龄本身不应成为使用芦可替尼的限制。
  • 高危分子突变的二代测序分析在老年患者中同样证实了很强的预测价值。

研究设计与样本

  • 在23个欧洲血液学中心建立临床数据库,回顾性分析291例在≥65岁时接受芦可替尼治疗的骨髓纤维化患者。
  • 对69例在芦可替尼治疗开始时有无外周血样本的患者,采用二代测序方法评估附加突变。

主要发现

  • 与65-74岁患者相比,≥75岁患者对芦可替尼的疗效相当,但药物诱导贫血和血小板减少发生率更高、生存更差。
  • 两年龄组的芦可替尼停药率相当。
  • 分子异常的数目和类型在各年龄组间相当。
  • 高危分子突变的存在显著影响生存,并对冲年龄效应。
  • ≥75岁且高危突变基因<2个的患者,生存与≥2个高危突变的65-74岁患者相当。

临床怎么用

  • 原文结论认为高龄本身不应成为使用芦可替尼的限制。
  • 原文结论认为二代测序分析高危分子突变在老年患者中同样有很强的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age. While aging is known to correlate with worse prognosis, no specific analysis is available to confirm that ruxolitinib is suitable for use in older populations. A clinical database was created in 23 European Haematology Centres and retrospective data on 291 MF patients treated with ruxolitinib when aged ≥65 years were analysed in order to assess the impact of age and molecular genotype on responses, toxicities and survival. Additional mutations were evaluated by a next generation sequencing (NGS) approach in 69 patients with available peripheral blood samples at the start of ruxolitinib treatment. Compared to older (age 65-74 years) patients, elderly (≥75 years) showed comparable responses to ruxolitinib, but higher rates of drug-induced anaemia and thrombocytopenia and worse survival. Nonetheless, the ruxolitinib discontinuation rate was comparable in the two age groups. Number and types of molecular abnormalities were comparable across age groups. However, the presence of high molecular risk (HMR) mutations significantly affected survival, counterbalancing the effect of aging. Indeed, elderly patients with <2 HMR mutated genes had a comparable survival to older patients with ≥2 HMR mutations. Given that responses were not influenced by age, older age per se should not be a limitation for ruxolitinib administration. NGS analysis of HMR mutations also confirmed a strong predictive value in elderly patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Palandri F, Catani L, Bonifacio M, et al. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. Br J Haematol. 2018. PMID: 30010187. doi:10.1111/bjh.15497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。